Triangle Biotechnology Awarded Grant by NIH to Develop Novel Sonication Reagent for High-Throughput DNA Shearing for NGS Applications
Chapel Hill, North Carolina (July 7, 2018) – Triangle Biotechnology, Inc., a pioneer in cutting edge life science sample prep solutions, today announced receipt of an approximately $300,000 Phase I SBIR grant from the National Institutes of Health (NIH) to support development of RapidShear®, a sonication reagent technology that enables high-throughput, high-quality, cost-effective DNA shearing solutions for next-generation sequencing (NGS) applications. In collaboration with Dr. Samantha Pattenden and Dr. Paul Dayton and their labs at the University of North Carolina at Chapel Hill, the project will leverage Triangle Biotechnology’s patented core technology designed to target and deliver precise mechanical shearing forces directly within each sample during sonication.
“We are delighted that the NIH has recognized the potential of our technology to further increase the throughput and accessibility of next-generation sequencing,” said Sunny Kasoji, PhD, Chief Technology Officer at Triangle Biotechnology. “With this award, Triangle Biotechnology can work toward our vision of giving every lab in the world the ability to rapidly and inexpensively shear DNA for next-generation sequencing applications.”
Successful completion of the Human Genome Project in 2003 established NGS as the gold standard technology for whole-genome, whole-exome, and targeted sequencing methodologies. NGS has led to an explosion of information on genetic diseases, new underlying pathways, novel mutations, and genotype–phenotype relationships. In the 15 years since sequencing technology became mainstream, the price of sequencing the human genome has dropped 100,000-fold owing to advancements in sequencing technologies and novel platforms. Despite the rapid advancements in sequencing, technologies surrounding biological sample preparation upstream of sequencing have not experienced a similar rate of advancement, leading to bottlenecks in the overall NGS workflow. With a rapidly growing focus on NGS technologies and a global market reaching $24 billion by 2023, there is an urgent need for better, faster, and cheaper sample preparation methods to facilitate continued technological improvements in the sequencing space.
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R43CA232902. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About Triangle Biotechnology:
Triangle Biotechnology, Inc. is dedicated to accelerating life science research and improving human health by delivering novel, effective, and efficient life science sample prep solutions. Applications include NGS, ChIP, ChIP-seq, mass spectometry and more from many different sample types. For more information, contact us at firstname.lastname@example.org.